Discontinued — last reported Q4 '25
Celestica Interest Paid increased by 38.1% to $18.50M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 25.0%, from $14.80M to $18.50M. Over 3 years (FY 2022 to FY 2025), Interest Paid shows relatively stable performance with a 0.8% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
An increase in interest paid relative to debt levels may signal rising borrowing costs or higher leverage, while a decrease may indicate debt reduction or refinancing at lower rates.
The total cash outflow for interest payments on debt obligations, typically disclosed as a supplemental item in the cash...
Essential for comparing the cost of capital and debt burden across peers in the pharmaceutical industry.
interest_paid| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $13.23M | $13.23M | $13.23M | $13.23M | $17.20M | $17.20M | $17.20M | $17.20M | $14.70M | $13.80M | $12.10M | $12.30M | $14.80M | $12.50M | $13.40M | $13.40M | $18.50M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | +30.1% | +0.0% | +0.0% | +0.0% | -14.5% | -6.1% | -12.3% | +1.7% | +20.3% | -15.5% | +7.2% | +0.0% | +38.1% |
| YoY Change | — | — | — | — | +30.1% | +30.1% | +30.1% | +30.1% | -14.5% | -19.8% | -29.7% | -28.5% | +0.7% | -9.4% | +10.7% | +8.9% | +25.0% |